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The proteome is highly variable and diﬀers from cell to cell. The reasons are posttranslational modiﬁcations, splice variants,
and polymorphisms. Techniques like next-generation sequencing can only give an inadequate picture of the protein status of
ac e l l .P r o t e i nm i c r o a r r a y sa r ea b l et ot r a c kt h e s ec h a n g e so nt h el e v e lt h e yo c c u r :t h ep r o t e o m i cl e v e l .T h e r e f o r e ,p r o t e i n
microarrays are powerful tools for relative protein quantiﬁcation, to unveil new interaction partners and to track posttranslational
modiﬁcations. This papers gives an overview on current protein microarray techniques and discusses recent advances in relative
protein quantiﬁcation.
1.Introduction
As early as 1998, B¨ ussow and coworkers [1] established a
technique to catalogue protein products of arrayed cDNA
clones.Closelyafterthissuccessfuleﬀorttoplotproteinsona
macroarray, Lueking and colleagues [2]w e r ea b l et op r o d u c e
protein microarrays from liquid expression cultures. They
used a transfer stamp mounted to a spotting robot, which
allowed the production of microarrays, setting a mark for
high-throughput ligand receptor interaction studies. Since
thattimecontactspottingforproteinmicroarrayshasmostly
been replaced by piezoelectric, contact-free, spotting. For
quantitative studies, it is mandatory that an equal amount
of volume is transferred each time a sample is spotted on
an array. Only this way, a highly reproducible array can be
produced and the generated data quantiﬁed. This criterion is
currently met only by piezoelectric spotting [3, 4].
In contrast to genomics, proteomics faces the fact that
the proteome diﬀers from organism to organism, between
diﬀerent tissues, and even between cells. Posttranslational
modiﬁcations, splice variants, and polymorphisms are lead-
ing to a proteome that is temporally and spatially highly
variable and diﬀers from cell to cell. Diﬀerent time points,
for example, due to diﬀerent states in the cell cycle or upon
external stimulus, lead to a diﬀerent protein composition
of the cell [5]. Expression analysis of cells and tissues gives
only an inadequate picture of the protein status in a cell.
In contrast to that, protein microarrays are able to track
these changes on the level they occur: the proteomic level.
Before an external stimulus leads to an altered transcription
proﬁle and is manifested in a diﬀerent proteome, the signal
is passed through the cell by a consecutive set of posttrans-
lational modiﬁcations of proteins. While analyzing signal
transduction pathways, the problem comes up that only a
subfraction of the whole proteome is of special interest. The
proteins of high interest are kinases, phosphatases, receptors,
ion channels, and transcription factors which are often low
abundant proteins within the cell [6]. Therefore, the relative
quantiﬁcationofproteinmodiﬁcationsisanimportantissue.
However,mostcelllysismethodsfailtoextractproteinsfrom
all cell compartments equally, and only a subfraction of this
lysate is spotted on arrays. Thus the immobilized samples
on slides represent only a small percentage of the whole
proteome. As a direct consequence, detection mechanisms
for the majority of proteins need to be very sensitive and
accurate.
2. Different Formats of Microarrays
T h et e r mm i c r o a r r a yi sac o l l e c t i v et e r mf o ram o d e r n
day technique used in research and development (R&D)2 Journal of Biomedicine and Biotechnology
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Figure 1: Modiﬁed from Hultschig et al. 2006 [7]. Diﬀerent types of protein microarrays with their diﬀerent substrates and detection
methods. (a) After immobilization and (b) after incubation with diﬀerent substrates.
as well as in in vitro diagnostics (ivD). Microarrays can
be used to address diﬀerent questions. Applications include
DNA, RNA, protein, lysate, and peptide arrays. Therefore,
they are able to cover proteomics and transcriptomics as
well as genomics. DNA microarrays can analyze the whole
transcriptome ofa cell,representedby over one million DNA
probes, whereas protein microarrays are mainly limited by
the number of proteins. All microarrays oﬀer the possibility
for miniaturization and parallelization. This way precious
sample material can be saved. Figure 1 depicts an overview
on diﬀerent microarray applications (a) and detection meth-
ods (b), which will be discussed in the following sections.
2.1. Antibody/Aptamer Arrays. Antibody microarrays and
protein microarrays are often described as forward microar-
rays. The forward-phase or normal-phase protein microar-
ray approach consists of the immobilization of a capture
molecule (e.g., antibodies or aptamers, also known as prey)
to a surface. The array is incubated with puriﬁed proteins,
antibodies, or cell extract and detected as bait. This can
be done either with directly labelled proteins or, in case of
an immobilized prey antibody, with a second antibody that
recognizes the bait (sandwich assay). Aptamers belong to the
family of nucleic acids. Due to their 3D structure, they are
a prominent compound used for target immobilization on
microarray surfaces. Aptamers are used as aﬃnity reagents
in biosensor applications, because they show less cross-
reactivity than antibodies do [8]. Antibody microarrays have
a broad ﬁeld of application; for instances, we mention the
following.
(i) Detection of toxins [9] in spiked milk, apple cider,
and blood samples; the detection limit was as low
as 10–100pg/mL, which shows the high sensitivity of
microarrays.
(ii) The progression of metastatic tissue can be detected
with diﬀerent markers [10]. Biomarkers are an im-
portant ﬁeld in cancer research. With the help of
antibody microarray experiments, up- and downreg-
ulation of several biomarkers involved in metastatic
progression could be observed. All experiments con-
ducted in this study showed correlation between pro-
tein microarray data and western blot experiments.
(iii) Detection of bacteria [11] was achieved by immobi-
lizing IgG onto gold nanoparticle probes, capturing
bacteria. Using antibody microarrays, discrimination
betweendiﬀerentbacterialstrainscouldbedonewith
as little as 103 cells per assay. In addition to that, the
capture could be inhibited by lipopolysaccharides,
allowing the detection of minimum inhibitory con-
centrations, which are a valuable clinical parameter.
2.2. Peptide Arrays. Peptide microarrays have the advantage
of being more stable than protein microarrays. The content
can be adapted to any scientiﬁc question. Additionally they
can be easily prepared and handled.
Kinase assays are a typical application for peptide mi-
croarrays, in order to screen for possible phosphorylation
sites [12]. Furthermore, they are often used for serum
proﬁlingofdiseases[13].Peptidescanbesynthesizeddirectly
on the surface [14, 15], or the peptides are covalentlyJournal of Biomedicine and Biotechnology 3
immobilized on modiﬁed glass slides [16]. To identify target
sites for kinases, the arrays are incubated either with cell
lysate or recombinant kinases. During the incubation step
radioactive labelled ATP is incorporated and can be detected
afterwards [17]. Allen and coworkers [18] were the ﬁrst ones
describing an alternative detection method to radioactive
labelled ATP with a similar sensitivity. Once a protein is
phosphorylated with this ATP derivate, it can be transferred
into a thiophosphate ester, which can be detected with a
speciﬁc antibody. One of the advantages is the ampliﬁcation
step that comes with the use of a secondary antibody, while
radioactive labelled ATP has no ampliﬁcation.
However, the use of peptide microarrays is not limited to
screen for kinase targets and the identiﬁcation of potential
phosphorylation sites or other posttranslational modiﬁca-
tions like monoaminylation, methylation, or glycosylation.
Excerpts from the ﬁelds of application include the following.
(i) The use of microarrays to identify peptides with
immunogenic potential [19]; by 2010, only 7% out
of 4000 open reading frames of M. tuberculosis have
been screened for T-cell epitopes. With a high-
throughput screening method like peptide microar-
rays, 7446 overlapping peptides from 61 individual
M. tuberculosis proteins were synthesized via the
SPOT technique [20] and used to identify new
potential T-cell epitopes.
(ii) The investigation of complex samples [21] using a
peptide library which especially targeted cysteine
proteases; cysteine proteases are involved in some
pathological conditions. A binding study conducted
with this library helped to ﬁnd not only speciﬁc
therapeutic inhibitors but also diagnostic markers.
When tested against apoptotic Hela and red blood
cells infected with Plasmodium falciparum,as p e c i ﬁ c
and reproducible binding pattern can be observed.
The obtained binding proﬁles could furthermore be
linked to various stages of the parasite infection.
(iii) The use, to monitor enzymatic activity of proteins,
for example, caspase activities; peptide microarrays
were used for the detection of on chip enzymatic
reactions, using the surface plasmon resonance tech-
nique. This way, lysates can be analyzed for their
caspase activity, which provides valuable information
for cell-based drug screening [22].
(iv) Solution-phase coupling of biotinylated synthetic
peptides to NeutrAvidin [23]. Antibodies are immo-
bilized to a NeutrAvidin-coated surface. Afterwards
they can be detected using ﬂuorescence-labelled sec-
ondary antibodies. With this technique, Andresen
and colleagues were able to detect low-picomolar
concentrations of monoclonal antibodies. These an-
tibodies have been diluted in human serum, which
demonstratesthepotentialofpeptidemicroarraysfor
serum screening.
2.3. Lysate Array. Reverse-phase protein microarrays
(RPMAs), also called lysate arrays, are generated by
immobilizing small amounts of whole cell lysate onto any
protein-binding surface. In principle RPMAs are minia-
turized Dot blots. They have the potential to analyze
small-quantity samples, at several time points, with diﬀerent
experimental settings and additionally several technical
replications at once [24]. Technologies like DNA and RNA
microarrays provide important results on expression levels,
but the direct consequences of these expressional changes
can hardly be assessed. Furthermore, they are unable to
detect posttranslational modiﬁcations, which may deﬁne the
phenotype and state of a cell [5]. Consequently the whole
repertoire of patients’ proteins, which represent the state of
individual diseased tissue cell population, can be analyzed
[25]. Quantitative immunoblotting [26]a n dM S[ 27]w e r e
used to make changes in protein levels visible; thus these
techniques require large amounts of cellular material [28],
whichisamajordrawbackforsystemsworkingwithprimary
material and/or stem cells. Additionally these techniques are
time consuming and expensive.
Using the reverse-phase approach, a lot of diﬀerent ques-
tions can be addressed; for instance, we mention the follow-
ing.
(i) The relative impact of miRNAs on target proteins
and their associated role in cellular processes [29];
because of diﬀerent regulatory eﬀects, it is hard to
predict the actual impact of miRNAs. Protein lysate
arrays are a tool to systematically monitor the eﬀect
on transfected cells. High-throughput transfections
inbreastcancercellsshowedthatoutof319miRNAs,
21downregulatedtheestrogenreceptor-a.Theresults
found by protein arrays could be veriﬁed by western
blot and qPCR.
(ii) The detection of tissue-based markers [30]; as stated
by Romeo and coworkers, lysate arrays measure
changesontheproteomiclevel.LikeRT-PCRandim-
munocytochemistry, lysate arrays have to be veriﬁed
and normalized, too.
(iii) Time-dependent signal transduction [31]; Dupuy
and colleagues investigated time-dependent phos-
phorylation pattern in complex signal transduction
pathways. The study correlated with western blot
analysis of the same samples while displaying excel-
lent intra- and interslide reproducibility. Looking
at the phosphorylation pattern of the transcription
factor CREB, RPMAs showed a positive signal after
one minute of stimulation with forskolin. Taken the
alreadyknownCREBactivationpatternintoaccount,
it can be estimated that the catalytic subunit of PKA
translocates into the nucleus in less than a minute (R.
Wellhausen, unpublished data).
These examples not only show the huge potential of reverse-
phase protein microarrays but also clarify that strict opera-
tion procedure and validation methods are mandatory when
working with lysate arrays. In the following section, key
aspects to reproducible, valid, and quantitative arrays will be
discussed.4 Journal of Biomedicine and Biotechnology
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Figure 2: Strategy for antibody validation; only if single bands can be detected, the antibody can be used in microarray experiments.
3. Validation of Antibodies/Detection
There are diﬀerent possibilities to detect the desired protein,
dependingonthearrayplatformchosen.Foranykindofpro-
tein microarray, the most common detection mechanisms
are
(1) labelling of the cell extract,
(2) direct or indirect detection with labelled antibodies.
Labeling of proteins works only for antibody microarrays
and has the disadvantage that it may mask the epitope;
therefore the antigen cannot bind to the ligand on the
surface [32]. Additionally a homogenous labelling of all
proteins is a diﬃcult task. Often high abundant proteins are
preferably modiﬁed whereas low abundant proteins such as
transcription factors are only rarely labelled.
Working with ﬂuorescently labelled detection antibodies
has the advantage of having a great dynamic range for
quantiﬁcation and signal ampliﬁcation. Nevertheless, the
antibodies should speciﬁcally detect their antigen and dis-
tinguish between closely related antigens. Lysate microarrays
do not allow diﬀerentiating between homolog proteins nor
do they separate proteins by their molecular mass. If the
antibody itself has cross-reactivity or detects more than
one antigen, the antibody cannot be used for a relative
quantiﬁcation. As a consequence the antibodies used in mi-
c r o a r r a ye x p e r i m e n t sm u s tb ew e l lc h a r a c t e r i z e d .G a r c i a
and coworkers [33] showed that validation of antibodies is
crucial. After validation, antibodies with a cross-reactivity
below 5% are selected, resulting in an analysis superior to
traditional ELISA.
For a reliable antibody performance the results of Am-
brozetal.[34]showedthatdetectionreagentsandconditions
should be held constant for both antibody validation and
microarray experiments. Diﬀerent extraction reagents and
methods lead to diﬀerent states of a protein either it is in
its native or in it is denaturated form [35]. To test if an
antibody is capable of binding the linearized (denaturated)
as well as the structured (native) form of the protein, all
antibodies should undergo a validation. Ideally the antibody
should yield a single band on a western blot (denatured
condition) [36] and additionally should be able to bind to
thenativeproteinduringimmunoprecipitationexperiments.
One prominent strategy to test the speciﬁcity and selectivity
is shown in Figure 2. If both, immunoprecipitation and
western blot results are positive, the antibodies can be used
in microarray experiments. The ﬁrst test is western blot
analysis. After SDS-PAGE, all proteins are denaturated; so, if
a single band in a western blot can be detected, the antibody
is capable of epitope recognition in their linearized (denatu-
rated) form. The second test is an immunoprecipitation. In
order to test whether the antibody binds to a native protein
or not, the cells are lysed under native conditions. If the
desired protein can be enriched via immunoprecipitation,
the antibody is able to detect native epitopes and can, if both
tests are passed positively, be used for readout and detection
in microarray experiments.
4.Blocking
Proteins are either bound covalently to the surface (e.g.,
epoxy surfaces) or via unspeciﬁc adsorption (e.g., mem-
brane). Taken the fact that it is not possible to cover the
entire surface with the desired target protein, the detection
antibody could bind unspeciﬁcally to the surface itself. This
adsorption onto the surface leads to a higher background.
Therefore the detection of a target protein is not only limited
by its concentration but also by the background signals [37].Journal of Biomedicine and Biotechnology 5
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Figure 3: (a) Nitrocellulose- (b) epoxy-coated slides. Both show images of a RPPM after blocking with 10% skim milk for 1 hour at 4◦C. (b)
shows almost no background, whereas nitrocellulose (a) has a high background.
Diﬀerent blocking buﬀers can have a signiﬁcant eﬀect on the
intensity of the background, as well as changes in blocking
conditions can inﬂuence antibody speciﬁcity [34]. To limit
these inﬂuences blocking solutions containing nonfat/low-
fat milk, bovine serum albumin, horse serum, or highly ﬂuo-
rinated organosilane are used to prevent nonspeciﬁc binding
of analytes [38]. On an epoxy-coated slide 10% skim milk
powder appears to be the best blocking solution, resulting
in the lowest background [39]. The direct comparison of a
RPMA array with a nitrocellulose-coated slide and an epoxy-
coatedslideafterblockingisdepictedinFigure 3.Botharra ys
were treated under the exact same conditions resulting in a
higher background for the nitrocellulose slide (a) than for
the epoxy-coated slide (b). When looking for low abundant
proteins, a low background is crucial for the detection and
analysis. The signal-to-noise ratio plays an important role
in R&D as well as in ivD, which will be discussed in the
following section.
5.Signal-to-Noise Ratio(SNR)
The signal-to-noise ratio is used in many diﬀerent appli-
cations. For microarrays, the SNR can help to distinguish
whether the signal is a true signal or whether it is too weak
to be considered for quantiﬁcation. The SNR is used for
all microarray applications to deﬁne positive signals. Only
if the SNR is above a certain threshold, it is considered
to be a true signal and can be used, for example, as a
diagnostic marker. Achievement of a high signal-to-noise
ratio gains even more importance when looking at low copy
and abundant proteins. Regularly these proteins give only
low-intensity signals. If the background is high, these signals
mightnotbedetectedproperly,ortheymightnotbedetected
at all.
According to Rampal and coworkers [40], the signal-to-
noise ratio is calculated as follows:
SNR
=
average signal intensity−average background intensity
standard deviations of background signals
.
(1)
SNR nitrocellulose coated slide
SNR epoxy coated slide
0 200 400 600 800 1000
Signal-to-noise ratio
H
SNR epoxy versus nitrocellulose
Figure 4: Comparison of the signal-to-noise ratio of the spots from
Figure 3.
There is a direct correlation between the slide surface (i.e.,
the natural occurring material background intensity and
the background intensity after blocking) and the SNR. As
depicted in Figure 5 the signal-to-noise ratio is higher for
epoxy-coated slides than for nitrocellulose-coated slides. The
demand for a high SNR comes with quantiﬁcation itself.
When it comes to R&D, sometimes a yes or no answer is
needed, which can also be given by a weak signal. Decisions
made with the help of in vitro diagnostics have to be as
certain as possible, in order to eliminate the number of false
positive or negative signals.
6. Mass Transport
After printing and blocking of a protein microarray, the
target molecules need to be detected.
AsdepictedinFigure 4,thesignal-to-noiseratioishigher
with epoxy-coated slides compared to nitrocellulose-coated6 Journal of Biomedicine and Biotechnology
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Figure 5: Mean versus median spot intensity for donut structures. Left-hand picture shows a protein spot with a typical donut structure
(orange line indicates the intensity intersection). Right-hand side: the intensity distribution is plotted (red and green line are mean and
median signal intensity of the spot).
slides. If the substrate allows immobilization on epoxy-
coated surfaces, it should be chosen over nitrocellulose-
coated slides.
When incubating protein microarrays with speciﬁc an-
tibodies, one limitation is the mass transport of the sample
and detection antibodies to the surface. In microspot im-
munoassays, the binding event of an antibody to an antigen
is slowed down by several orders of magnitude compared
to well-stirred bulk reactions. Therefore several factors need
to be taken under consideration: buﬀer viscosity, no mixing
or imperfect mixing of the array, incubation time, ana-
lyte concentration, and the use of antibodies with higher
aﬃnities [41]. Sometimes it is not possible to take all
these points under consideration, the buﬀer composition for
certain extraction procedures cannot be changed, or there
is no antibody available that has a higher aﬃnity. Up to
a certain level, it is possible to make up for these issues
with elongated incubation times and improved mixing. To
overcome the problems of mass transport, the mixing and
washing volumes are crucial parameters. If working with
a gasket/chamber system, the applicable volume is limited.
Therefore the incubation and washing times have to be
extended.
7. Mean versus Median
Protein spots often come with a ring-shaped structure,
referred to as donut structure. During the formation of
such a structure, the proteins are accumulating at the outer
boundary of a spot. This particular structure makes it hard
to analyze the signal, because the intensity is unevenly
distributed throughout the spot. The intensity/pixel ratio is
much higher on the outer rim than in the middle of the spot.
To overcome this problem, spotting and drying conditions
have to be optimized dependent on the immobilization
chemistry, the buﬀer used, and several other factors. Humid-
ityinthespottingchambercanberegulated,sothatthespots
will not dry immediately after being dispensed. However,
thesechangesnotguaranteetoovercometheoccurringprob-
lems of ring-shaped structures. During drying the proteins
are accumulating preferably at the outer boundary of the
spots. Zhu and Guo [42] state that protein molecules are
known to preferentially accumulate at air/water interfaces.
Detergents like Triton X-100 lower the surface tension of the
spotting mix and can be used to reduce this eﬀect.
However, if the above-mentioned methods fail and the
donut-shaped structure persists, it can be mathematically
adjusted. Measuring the mean and median spot intensities
gives an idea of the actual value. If the gray value is
distributed as shown in Figure 5, it makes more sense to
take the median intensity, to really cover the majority of
all values. If the spot has a homogeneous morphology,
both values mean and median are almost the same. After
that, it comes to a case-to-case decision where it has to be
mathematically and statistically evaluated if the signal has to
be excluded from the array.
8. Normalization
Normalization and standardization of samples, microarrays,
and microarray data itself are of importance. As far asJournal of Biomedicine and Biotechnology 7
changes on the proteomic level are concerned, small changes
of PTMs or the expression level itself matter. However, these
small changes cannot be estimated if, for example, the dif-
ferent lysates on the arrays are not spotted under equimolar
conditions. Therefore, the samples have to be quantiﬁed
before spotting using techniques like BCA or Bradford. The
total amount of bound protein can be determined after
spotting and washing but before further processing like
blocking. If the amount of total protein diﬀers from spot
to spot, the signal intensities can be normalized within one
array and between diﬀerent slides. This way, fold changes of
proteins or their PTM status (via antibody detection) can be
accurately detected and interpreted correctly.
9. Conclusion
Protein microarrays are a powerful tool not only to identify,
for example, new interaction partners or posttranslational
modiﬁcations, but also for relative protein quantiﬁcation.
They contribute greatly to the investigation and under-
standing of the proteome on a quantitative level. During
the last years, a lot of work and eﬀort has been put into
optimizing protocols and standard operation procedures.
These procedures should be carried out at all times when
working with protein microarrays. All antibodies used in
array experiments have to be controlled beforehand, to
make sure that the detected signals are valid. Commercially
available antibodies are marked for their intended use, for
example, recommended for use in immunohistochemistry,
western blot analysis, or immunoprecipitation. The same
kind of information should be provided for the use of
antibodies in microarray experiments. The slides’ surface has
to be chosen carefully in order to ﬁnd a suitable platform
for each individual purpose. Blocking buﬀers have to be
optimized each time the surface changes and should be
kept constant for both the validation of antibodies and the
array experiments itself. Incubation should be carried out
under conditions limiting mass transport problems. The
SNR should be critically observed at all times to be sure
that the signal can be quantiﬁed. The individual structure
f o re a c hs p o th a st ob ed e t e r m i n e di no r d e rt oﬁ n da
suitable mathematical model for analysis. If all these points
are taken care of, protein microarrays will greatly contribute
to help understanding proteomic procedures and will play
an important role in clinical diagnostics as well as in research
and development.
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